|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Department of Veterans Affairs |
|---|---|
| Information provided by: | Department of Veterans Affairs |
| ClinicalTrials.gov Identifier: | NCT00101361 |
Purpose
This study is designed to determine whether the use of oxandralone, an anabolic steroid, can heal pressure ulcers in persons with spinal cord injury (SCI). In a Feasibility Study, three VA SCI Units will screen and randomize patients into treatment with oxandralone or with placebo. Eleven other sites will screen patients to determine eligibility but will not treat patients with the agent. Following the Feasibility Study, all sites will participate in a blinded, randomized treatment study. A total of 400 patients will be enrolled over a four-year period. Any patient in a participating unit who has chronic SCI and a difficult-to-heal pelvic ulcer will be eligible for the study if other entry criteria are met. All enrolled patients will be followed for a period of 24 weeks to determine whether their target pressure ulcers heal. Those who are healed will be followed for an additional four weeks to determine whether the ulcer remains healed.
| Condition | Intervention | Phase |
|---|---|---|
|
Pressure Ulcer |
Drug: Oxandrolone Drug: Placebo |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | CSP #535 - Anabolic Steroid Therapy on Pressure Ulcer Healing in Persons With Spinal Cord Injury |
| Enrollment: | 212 |
| Study Start Date: | August 2005 |
| Study Completion Date: | December 2008 |
| Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
oxandrolone
|
Drug: Oxandrolone
Patients will receive oxandrolone (10mg BID) until full healing occurs or for 24 weeks, whihc ever comes first.
|
|
Placebo Comparator: 2
placebo
|
Drug: Placebo
Patients will receive an identically appearing placebo capsule until full healing occurs or for 24 weeks, whihc ever comes first.
|
The primary objective is to determine whether SCI inpatients with a chronic Stage III or IV pressure ulcer of the pelvic region who are randomized to receive 24 weeks of optimized clincial care and an oral anabolic steroid agent (oxandrolone) will have a greater percent of healed pressure uclers than those who receive placebo and the same optimized clincial care. The major secondary objective is to determine whether the healed pressure ulcer will remain healed for at least 8 weeks.
Subjects are registered into a 4 week screening phase to be followed with weekly photos of the ulcer and if healed less than 30% (from the day 1 photo to the day 28 photo) with standard clincial care, they are introduced to the treatment phase (randomized) and followed for another 24 weeks on either oxandrolone or placebo. Wounds that heal (remain closed for at least 96 hours) are then subject to 2 four week follow up visits.
Criteria for entering the screening phase are simple: either gender, age 18 years or older, inpatient with SCI or equivalent spinal cord damage and at least 1 Stage III or IV (indicating a severe wound, <260cm2) pressure ulcer of the pelvic region.
September 2006 - year one report submitted and approved by Central Office. Plan to add up to 3 more sites in the next year.
January 2007 - site #16 (San Antonio) is approved by CO to be invited.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
SCREENING PHASE:
TREATMENT PHASE:
1. documentation (through screening phase) of difficult to heal (defined as <30% area reduction) or worsening status of the pressure ulcer for at least 28 days as inpatient (screening phase)
Exclusion Criteria:
SCREENING PHASE:
TREATMENT PHASE:
Contacts and Locations| United States, California | |
| VA Medical Center, Long Beach | |
| Long Beach, California, United States, 90822 | |
| VA Palo Alto Health Care System | |
| Palo Alto, California, United States, 94304-1290 | |
| VA San Diego Healthcare System, San Diego | |
| San Diego, California, United States, 92161 | |
| United States, Florida | |
| VA Medical Center, Miami | |
| Miami, Florida, United States, 33125 | |
| James A. Haley Veterans Hospital, Tampa | |
| Tampa, Florida, United States, 33612 | |
| United States, Georgia | |
| VA Medical Center, Augusta | |
| Augusta, Georgia, United States, 30904 | |
| United States, Illinois | |
| Edward Hines, Jr. VA Hospital | |
| Hines, Illinois, United States, 60141-5000 | |
| United States, Massachusetts | |
| VA Boston Healthcare System, Brockton Campus | |
| Brockton, Massachusetts, United States, 02301 | |
| United States, Missouri | |
| VA Medical Center, St Louis | |
| St Louis, Missouri, United States, 63106 | |
| United States, New York | |
| VA Medical Center, Bronx | |
| Bronx, New York, United States, 10468 | |
| United States, Ohio | |
| VA Medical Center, Cleveland | |
| Cleveland, Ohio, United States, 44106 | |
| United States, Texas | |
| VA North Texas Health Care System, Dallas | |
| Dallas, Texas, United States, 75216 | |
| Michael E. DeBakey VA Medical Center (152) | |
| Houston, Texas, United States, 77030 | |
| United States, Virginia | |
| Hunter Holmes McGuire VA Medical Center | |
| Richmond, Virginia, United States, 23249 | |
| United States, Wisconsin | |
| Zablocki VA Medical Center, Milwaukee | |
| Milwaukee, Wisconsin, United States, 53295-1000 | |
| Puerto Rico | |
| VA Medical Center, San Juan | |
| San Juan, Puerto Rico, 00921 | |
| Study Chair: | William Bauman, MD | VA Medical Center, Bronx |
More Information
| Responsible Party: | Bauman, William - Study Chair, Department of Veterans Affairs |
| ClinicalTrials.gov Identifier: | NCT00101361 History of Changes |
| Other Study ID Numbers: | 535 |
| Study First Received: | January 7, 2005 |
| Last Updated: | January 29, 2009 |
| Health Authority: | United States: Federal Government; United States: Food and Drug Administration |
|
dermatologic, skin, clinical trial, androgen/anabo |
|
Pressure Ulcer Spinal Cord Injuries Ulcer Skin Ulcer Skin Diseases Spinal Cord Diseases Central Nervous System Diseases Nervous System Diseases Trauma, Nervous System |
Wounds and Injuries Pathologic Processes Oxandrolone Anabolic Agents Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions Androgens |